Emerging role of FBXO22 in carcinogenesis

Jiangting Cheng; Min Lin; Man Chu; Longyuan Gong; Yanli Bi; Yongchao Zhao

doi:10.1038/s41420-020-00303-0

Emerging role of FBXO22 in carcinogenesis

Cell Death Discov. 2020 Jul 27:6:66. doi: 10.1038/s41420-020-00303-0. eCollection 2020.

Authors

Jiangting Cheng^{1

2}, Min Lin³, Man Chu³, Longyuan Gong^{1

2}, Yanli Bi^{1

2}, Yongchao Zhao^{1

2}

Affiliations

¹ Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
² Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China.
³ The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Abstract

The F-box protein 22 (FBXO22), one of F-box proteins, has been identified to be critically involved in carcinogenesis. FBXO22 promotes proliferation in breast cancer and lung cancer, but suppresses migration and metastasis. FBXO22 exerts oncogenetic functions via promoting the ubiquitination and degradation of its substrates, including KDM4A, KDM4B, methylated p53, p21, KLF4, LKB1, Snail, CD147, Bach1, PTEN, and HDM2. FBXO22 is also regulated by several regulatory factors such as p53, miR-155, SNHG14, and circ_0006282. In this review, we summarize the regulatory factors and downstream targets of FBXO22 in cancers, discuss its functions in tumorigenesis, and further highlight the alteration of FBXO22 expression in a variety of human malignancies. Finally, we provide novel insights for future perspectives on targeting FBXO22 as a promising strategy for cancer therapy.

Keywords: Ubiquitin ligases; Ubiquitylation.

Publication types

Review